SCHEMBL15980400

SCHEMBL15980400

CN1CCc2cn(C)nc2C1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.45
MAOB P27338 4/20 0.45
DRD4 P21917 3/20 0.41
DRD2 P14416 1/20 0.41
DRD1 P21728 1/20 0.41
DRD5 P21918 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A4 P31645 1/20 0.39
NAMPT P43490 1/20 0.38
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12489993 0.84 MAOA (0.45) MAOAMAOBDRD4DRD2DRD1
SCHEMBL17624280 0.83 DRD4 (0.35) MAOAMAOBDRD4DRD2NAMPT
SCHEMBL20117307 0.78 MAOA (0.40) MAOAMAOBDRD4DRD2DRD1
SCHEMBL18034940 0.78 MAOA (0.40) MAOAMAOBDRD4DRD2DRD1
SCHEMBL19164014 0.78 NAMPT (0.35) DRD4NAMPT
SCHEMBL18034942 0.73 HDAC9 (0.40) MAOAMAOBDRD4DRD2DRD1
SCHEMBL8001513 0.72
SCHEMBL7996526 0.72 DRD4 (0.46) DRD4DRD2
SCHEMBL29341580 0.72 PDK2 (0.33) DRD4NAMPT
SCHEMBL16181322 0.69 MAOA (0.47) MAOAMAOBDRD4DRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220402917-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2022-12-22 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
EP-4043461-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2022-08-17 EP disclosed
WO-2021063404-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF 南京明德新药研发有限公司 2021-04-08 WO disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP MAOA 135/4885MAOB 225/4885DRD4 1861/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH MAOA 182/4885MAOB 165/4885DRD4 1036/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP MAOA 135/4885MAOB 225/4885DRD4 1861/4885
US-20220402917-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF CD274, PDCD1, PDCD1LG2 MAOA 2600/4885MAOB 2716/4885DRD4 4104/4885
US-20140243310-A1 BICYCLIC COMPOUND BICRA, NR3C2, CYP11B2 MAOA 2534/4885MAOB 1923/4885DRD4 852/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP MAOA 135/4885MAOB 225/4885DRD4 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.